In Silico Strategies for Prospective Drug Repositionings

The discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new a...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (288 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993576078704498
ctrlnum (CKB)5470000001633477
(oapen)https://directory.doabooks.org/handle/20.500.12854/95899
(EXLCZ)995470000001633477
collection bib_alma
record_format marc
spelling Udrescu, Lucreția edt
In Silico Strategies for Prospective Drug Repositionings
Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
1 electronic resource (288 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
The discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new anticancer drugs, new antivirals).Within this framework, drug repositioning—finding new pharmacodynamic properties for already approved drugs—becomes a worthy drug discovery strategy.Recent drug discovery techniques combine traditional tools with in silico strategies to identify previously unaccounted properties for drugs already in use. Indeed, big data exploration techniques capitalize on the ever-growing knowledge of drugs' structural and physicochemical properties, drug–target and drug–drug interactions, advances in human biochemistry, and the latest molecular and cellular biology discoveries.Following this new and exciting trend, this book is a collection of papers introducing innovative computational methods to identify potential candidates for drug repositioning. Thus, the papers in the Special Issue In Silico Strategies for Prospective Drug Repositionings introduce a wide array of in silico strategies such as complex network analysis, big data, machine learning, molecular docking, molecular dynamics simulation, and QSAR; these strategies target diverse diseases and medical conditions: COVID-19 and post-COVID-19 pulmonary fibrosis, non-small lung cancer, multiple sclerosis, toxoplasmosis, psychiatric disorders, or skin conditions.
English
Medicine bicssc
Pharmaceutical industries bicssc
COVID-19
drug repurposing
topological data analysis
persistent Betti function
SARS-CoV-2
network-based pharmacology
combination therapy
nucleoside GS-441524
fluoxetine
synergy
antidepressant
natural compounds
QSAR
molecular docking
drug repositioning
UK Biobank
vaccine
LC-2/ad cell line
drug discovery
docking
MM-GBSA calculation
molecular dynamics
cytotoxicity assay
GWAS
multiple sclerosis
oxidative stress
repurposing
ADME-Tox
bioinformatics
complex network analysis
modularity clustering
ATC code
hidradenitis suppurativa
acne inversa
transcriptome
proteome
comorbid disorder
biomarker
signaling pathway
druggable gene
drug-repositioning
MEK inhibitor
MM/GBSA
Glide docking
MD simulation
MM/PBSA
single-cell RNA sequencing
pulmonary fibrosis
biological networks
p38α MAPK
allosteric inhibitors
in silico screening
computer-aided drug discovery
network analysis
psychiatric disorders
medications
psychiatry
mental disorders
toxoplasmosis
Toxoplasma gondii
in vitro screening
drug targets
drug-disease interaction
target-disease interaction
DPP4 inhibitors
lipid rafts
3-0365-6134-X
Kurunczi, Ludovic edt
Bogdan, Paul edt
Udrescu, Mihai edt
Udrescu, Lucreția oth
Kurunczi, Ludovic oth
Bogdan, Paul oth
Udrescu, Mihai oth
language English
format eBook
author2 Kurunczi, Ludovic
Bogdan, Paul
Udrescu, Mihai
Udrescu, Lucreția
Kurunczi, Ludovic
Bogdan, Paul
Udrescu, Mihai
author_facet Kurunczi, Ludovic
Bogdan, Paul
Udrescu, Mihai
Udrescu, Lucreția
Kurunczi, Ludovic
Bogdan, Paul
Udrescu, Mihai
author2_variant l u lu
l k lk
p b pb
m u mu
author2_role HerausgeberIn
HerausgeberIn
HerausgeberIn
Sonstige
Sonstige
Sonstige
Sonstige
title In Silico Strategies for Prospective Drug Repositionings
spellingShingle In Silico Strategies for Prospective Drug Repositionings
title_full In Silico Strategies for Prospective Drug Repositionings
title_fullStr In Silico Strategies for Prospective Drug Repositionings
title_full_unstemmed In Silico Strategies for Prospective Drug Repositionings
title_auth In Silico Strategies for Prospective Drug Repositionings
title_new In Silico Strategies for Prospective Drug Repositionings
title_sort in silico strategies for prospective drug repositionings
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2022
physical 1 electronic resource (288 p.)
isbn 3-0365-6133-1
3-0365-6134-X
illustrated Not Illustrated
work_keys_str_mv AT udresculucretia insilicostrategiesforprospectivedrugrepositionings
AT kuruncziludovic insilicostrategiesforprospectivedrugrepositionings
AT bogdanpaul insilicostrategiesforprospectivedrugrepositionings
AT udrescumihai insilicostrategiesforprospectivedrugrepositionings
status_str n
ids_txt_mv (CKB)5470000001633477
(oapen)https://directory.doabooks.org/handle/20.500.12854/95899
(EXLCZ)995470000001633477
carrierType_str_mv cr
is_hierarchy_title In Silico Strategies for Prospective Drug Repositionings
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
noLinkedField
noLinkedField
noLinkedField
noLinkedField
_version_ 1796652733036494848
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04891nam-a2201165z--4500</leader><controlfield tag="001">993576078704498</controlfield><controlfield tag="005">20231214133552.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202301s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-6133-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5470000001633477</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/95899</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995470000001633477</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Udrescu, Lucreția</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">In Silico Strategies for Prospective Drug Repositionings</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (288 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The discovery of new drugs is one of pharmaceutical research's most exciting and challenging tasks. Unfortunately, the conventional drug discovery procedure is chronophagous and seldom successful; furthermore, new drugs are needed to address our clinical challenges (e.g., new antibiotics, new anticancer drugs, new antivirals).Within this framework, drug repositioning—finding new pharmacodynamic properties for already approved drugs—becomes a worthy drug discovery strategy.Recent drug discovery techniques combine traditional tools with in silico strategies to identify previously unaccounted properties for drugs already in use. Indeed, big data exploration techniques capitalize on the ever-growing knowledge of drugs' structural and physicochemical properties, drug–target and drug–drug interactions, advances in human biochemistry, and the latest molecular and cellular biology discoveries.Following this new and exciting trend, this book is a collection of papers introducing innovative computational methods to identify potential candidates for drug repositioning. Thus, the papers in the Special Issue In Silico Strategies for Prospective Drug Repositionings introduce a wide array of in silico strategies such as complex network analysis, big data, machine learning, molecular docking, molecular dynamics simulation, and QSAR; these strategies target diverse diseases and medical conditions: COVID-19 and post-COVID-19 pulmonary fibrosis, non-small lung cancer, multiple sclerosis, toxoplasmosis, psychiatric disorders, or skin conditions.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industries</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug repurposing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">topological data analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">persistent Betti function</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SARS-CoV-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">network-based pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combination therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nucleoside GS-441524</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fluoxetine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">synergy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antidepressant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">natural compounds</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">QSAR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular docking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug repositioning</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">UK Biobank</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LC-2/ad cell line</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug discovery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">docking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MM-GBSA calculation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular dynamics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytotoxicity assay</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">GWAS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multiple sclerosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxidative stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">repurposing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADME-Tox</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioinformatics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">complex network analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">modularity clustering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ATC code</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hidradenitis suppurativa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acne inversa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proteome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">comorbid disorder</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">signaling pathway</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">druggable gene</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug-repositioning</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MEK inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MM/GBSA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Glide docking</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MD simulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MM/PBSA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">single-cell RNA sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biological networks</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">p38α MAPK</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">allosteric inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in silico screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">computer-aided drug discovery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">network analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">psychiatric disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medications</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">psychiatry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mental disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">toxoplasmosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Toxoplasma gondii</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vitro screening</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug targets</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug-disease interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target-disease interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DPP4 inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lipid rafts</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-6134-X</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kurunczi, Ludovic</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bogdan, Paul</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Udrescu, Mihai</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Udrescu, Lucreția</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kurunczi, Ludovic</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bogdan, Paul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Udrescu, Mihai</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:58:03 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-01-18 06:03:23 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5343016930004498&amp;Force_direct=true</subfield><subfield code="Z">5343016930004498</subfield><subfield code="b">Available</subfield><subfield code="8">5343016930004498</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5342572760004498&amp;Force_direct=true</subfield><subfield code="Z">5342572760004498</subfield><subfield code="b">Available</subfield><subfield code="8">5342572760004498</subfield></datafield></record></collection>